EXT608

DB18453InvestigationalProtein Based Therapies

EXT608 is a long-acting PTH derivative under investigation for the treatment of hyperparathyroidism.

Code names
EXT-608

What you can answer from here — as of April 23, 2025

2Clinical trialsPhase, status and sponsor resolved per trial
Sign in
1+ReferenceStructured and connected to the statements they support
Sign in

Which companies are running trials of EXT608, in which indications and phases, and which of those programs are still active?

Answer this in Biopharma OSSign in to your account

Create a free account or log in to explore the full data card.

Create Account
Log InPaid Account Log In